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Summary
Background To eradicate yaws, national control programmes use the Morges strategy (initial mass treatment and 
biannual resurveys). The resurvey component is designed to actively detect and treat remaining yaws cases and is 
initiated on the basis of laboratory-supported reactive non-treponemal serology (using the rapid plasma reagin [RPR] 
test). Unfortunately, the RPR test is available rarely in yaws-endemic areas. We sought to assess a new point-of-care 
assay—the Dual Path Platform (DPP) syphilis assay, which is based on simultaneous detection of antibodies to 
treponemal and non-treponemal antigens—for guiding use of antibiotics for yaws eradication. A secondary goal was 
to ascertain at what timepoint the DPP assay line reverted to negative after treatment.
Methods 703 children (aged 1–18 years) with suspected clinical yaws living in two remote, yaws-endemic villages in 
Papua New Guinea were enrolled. Clinical suspicion of yaws was established according to a WHO pictorial guide. We 
obtained blood samples from all patients. We calculated the sensitivity and speciﬁ city of the DPP assay for detection 
of antibodies to treponemal (T1) and non-treponemal (T2) antigens and compared values against those obtained with 
standard laboratory tests (the Treponema pallidum haemagglutination assay [TPHA] and the RPR test). We followed up 
a subsample of children with dually positive serology (T1 and T2) to monitor changes in DPP optical density (using 
an automatic reader) at 3 and 6 months. This trial is registered with ClinicalTrials.gov, number NCT01841203.
Findings Of 703 participants, 389 (55%) were reactive for TPHA, 305 (43%) for the RPR test, and 287 (41%) for both 
TPHA and the RPR test. The DPP T1 (treponemal) assay had a sensitivity of 88·4% (95% CI 84·8–91·4) and speciﬁ city 
of 95·2% (92·2–97·3). The DPP T2 (non-treponemal) assay had a sensitivity of 87·9% (83·7–91·3) and speciﬁ city of 
92·5% (89·4–94·9). In subgroup analyses, sensitivities and speciﬁ cities did not diﬀ er according to type of specimen 
(plasma vs whole blood). For specimens with an RPR titre of 1:8 or greater, the sensitivity of the DPP T2 assay was 
94·1% (95% CI 89·9–96·9). Serological cure (including seroreversion or a fourfold reduction in optical density value) 
was attained at 6 months in 173 (95%) of 182 children with dual-positive serology.
Interpretation The DPP assay is accurate for identiﬁ cation of antibodies to treponemal and non-treponemal antigens 
in patients with yaws and avoids the need for laboratory support. A change of diagnostic procedure from the currently 
implemented RPR test to the simpler DPP assay could ease the implementation of yaws eradication activities.
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Introduction
Yaws is a neglected tropical disease caused by 
Treponema pallidum pertenue and closely related to 
syphilis. The ﬁ rst sign of infection—a localised papule—
is apparent after an incubation period of 10–90 days. 
Secondary disseminated cutaneous lesions and tertiary 
destructive lesions of the bones develop with relapsing or 
persistent infection.1 According to the WHO simpliﬁ ed 
pictorial guide,2 yaws is suspected if multiple papillomas, 
non-tender ulcers, bone lesions, or plantar hyperkeratosis 
are present.
Syphilis serological testing has been used in the ﬁ eld 
to assist with diagnosis of yaws infections. Traditionally, 
individuals in whom seropositivity for syphilis correlates 
with clinical signs and symptoms of yaws are presumed 
to have yaws. Serological diagnosis of yaws requires 
detection of two distinct antibodies: one against 
a treponemal antigen and one against a non-treponemal 
antigen. Non-treponemal agglutination tests (eg, the 
rapid plasma reagin [RPR] test, and the VDRL slide test) 
become reactive during the initial stage of infection 
and generally revert to negative after treatment.3–5 
By contrast, treponemal serological tests (eg, the 
T pallidum haemagglutination assay [TPHA], the 
T pallidum particle agglutination assay [TPPA], and the 
ﬂ uorescent treponemal antibody absorption [FTA-Abs] 
test) remain reactive for life, despite treatment.6,7 Thus, 
non-treponemal tests are a better indication of active 
infection and ongoing transmission in an area.
WHO has targeted yaws for eradication by 20208 and 
has developed the Morges strategy, which comprises 
initial mass treatment followed by surveys every 6 months 
to actively detect and treat remaining cases.9,10 Use of one 
oral dose of azithromycin11 has made mass treatment 
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simpler, and WHO studies are underway to conﬁ rm 
eﬃ  cacy of this strategy. During retreatment surveys, 
accurate identiﬁ cation of patients with active infection 
who need antibiotics is done with non-treponemal tests 
(ie, the RPR test or VDRL slide test),3–5 but these diagnostic 
procedures entail use of a sample of serum and must be 
done in laboratory settings that are rarely available in 
yaws-endemic areas. Decisions for continued targeted 
intervention could be made on the basis of commercially 
available point-of-care treponemal tests.12,13 Unfortunately, 
treponemal test results correlate poorly with presence of 
active infection, particularly after one or more rounds of 
mass treatment. Therefore, monitoring the eﬀ ect of 
biannual mass administration of antibiotics with 
treponemal tests alone is likely to result in unnecessary 
and costly treatment and could increase the probability of 
selection for antibiotic-resistant pathogens.14
A point-of-care immunoassay that simultaneously 
detects antibodies to non-treponemal and treponemal 
antigens was developed for diagnosis of syphilis, and the 
test is expected to work for yaws.15–17 The assay—Dual Path 
Platform (DPP) Syphilis Screen and Conﬁ rm (Chembio 
Diagnostic Systems, Medford, NY, USA)—is designed for 
use in resource-limited settings where challenging 
conditions (such as lack of electricity, running water, or 
laboratory equipment) commonly exist.16 We sought to 
compare the DPP assay for diagnosis of yaws infection 
with TPHA and the RPR test as reference standards. A 
secondary aim of our study was to estimate the changes 
in DPP optical density values among children with 
positive non-treponemal and treponemal antibodies 
3 and 6 months after treatment.
Methods
Participants
We recruited participants from Lihir Island villages in the 
New Ireland province of Papua New Guinea in April, 2013 
(referred to as group 1), and from Karkar Island in the 
Madang province of Papua New Guinea in October, 2013 
(referred to as group 2). We selected these communities 
because they have a fairly high prevalence of yaws in 
children.18,19 We undertook community-based surveys 
and invited children aged 1–18 years, who were suspected 
to have yaws by clinical examination, to participate in 
the study.
We obtained approval for the study from the 
National Medical Research Advisory Committee of the 
Papua New Guinea Ministry of Health (MRAC 
approval 13.25). All participants, or their parents, 
provided signed informed consent.
Procedures
Two clinicians (PM and RW) with extensive experience in 
diagnosing yaws examined and classiﬁ ed participants 
according to the WHO yaws pictorial guide.2 We took a 
venous blood sample from every individual and stored it 
in an EDTA tube for testing with the DPP assay and the 
standard reference tests. At the end of every clinic day, 
we transported blood tubes to the local hospital. 
A laboratory technician separated plasma and froze 
samples at –20°C until they could be transferred to the 
Lihir Medical Centre laboratory for further serology 
testing. On Lihir Island (group 1), a technician did the 
DPP assay in the Lihir Medical Centre laboratory with the 
plasma specimens that were frozen before testing. On 
Karkar Island (group 2), a community health worker did 
the DPP assay in the ﬁ eld using ﬁ nger-stick whole-blood 
samples. The two types of specimen—plasma and whole 
blood—could not be tested for every patient because of 
diﬃ  culties implementing the study in the rural regions. 
Laboratory technicians undertook RPR tests and TPHA 
for both groups at the Lihir Medical Centre laboratory. 
These technicians randomly selected (using a random 
number generator and numbered samples) 5% of reactive 
and non-reactive samples and sent these to an 
independent microbiology unit (Sullivan Nicolaides 
Pathology, QLD, Australia), at which TPHA and the RPR 
test were repeated for quality assurance.
We gave one oral dose of azithromycin (30 mg/kg) 
to participants with reactive treponemal and 
non-treponemal serology. We followed up children 
in group 1 who were dually positive by DPP assay, 
to monitor changes in optical density 3 and 6 months 
after treatment. 
The DPP Syphilis Screen and Conﬁ rm assay (Chembio 
Diagnostic Systems) is a point-of-care immuno-
chromatographic device that detects IgG and IgM 
antibodies to treponemal (T1) and non-treponemal (T2) 
antigens.15 It contains two nitrocellulose membrane strips 
perpendicular to each other that allow independent 
delivery of the test sample and the detecting protein A and 
anti-IgM conjugate reagents. The speciﬁ city of the assay 
for syphilis was established previously against a panel of 
serum samples obtained from patients with 17 infectious 
diseases other than syphilis.15 Furthermore, the point-of-
care assay also identiﬁ ed correctly all 105 serum samples 
from patients with known stages of syphilis.15
To do the DPP assay, we used 10 mL of blood or 5 mL of 
the plasma sample; we adhered strictly to the 
manufacturer’s instructions. One clinician read the 
results of the DPP assay by naked eye and recorded it in a 
data collection form. A diﬀ erent clinician, who was 
unaware of the naked-eye value, inserted the DPP assay 
cartridge into an automatic reader device (Chembio 
Diagnostic Systems) that measures numerically the 
optical density of each test line and stores the results. 
To ascertain DPP assay positivity, the manufacturer 
recommends cutoﬀ  values of optical density of either 
greater than 35 or greater than 50. Preliminary data15 
indicate that the density of the non-treponemal line 
correlates with RPR titres. Laboratory technicians at 
Lihir Medical Centre did TPHA (Human Diagnostics, 
Wiesbaden, Germany) and the qualitative and quantitative 
RPR test (Human Diagnostics) and took measurements 
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according to the manufacturers’ instructions. The 
laboratory technicians who did the standard tests and read 
the results were unaware of the results of the DPP assay.
Statistical analysis
We calculated that a sample size of at least 579 people 
would give 80% power to estimate overall sensitivity and 
speciﬁ city of the DPP assay in our study. We based our 
calculation on the expected sensitivity and speciﬁ city of the 
DPP assay of 95%,15 ﬁ xed precision of the point estimate of 
3%, and an estimated frequency of a positive TPHA or 
RPR test, or both, in the study population of 65%.18
To calculate sensitivity and speciﬁ city of the DPP T1 
(treponemal line) assay, we compared DPP T1 assay 
positivity identiﬁ ed by the naked eye with results of TPHA. 
To ascertain sensitivity and speciﬁ city of the DPP T2 (non-
treponemal line) assay, we compared DPP T2 assay 
positivity identiﬁ ed by either the naked eye or automated 
reader (at recommended cutoﬀ s of >35 or >50) with results 
of the RPR test. We did additional analyses to assess 
whether accuracy of results was consistent across 
subgroups deﬁ ned according to disease stage (primary or 
secondary) or type of specimen (plasma or whole blood). 
We also compared the DPP T2 assay with RPR titres of 1:8 
or higher, which have been judged the marker for true 
infection in past yaws studies.20 We used Fisher’s exact test 
to compare the sensitivity of the DPP T2 assay between 
RPR titres of 1:4 or less and 1:8 or greater.
We used a log-normal regression model to test whether 
intensity of the DPP T2 (non-treponemal line) point-of-
care assay measured by automatic reader grew with 
increasing RPR titre. To establish whether the automated 
reader could augment the performance of the DPP T2 
assay, we used McNemar’s test to compare the sensitivity 
and speciﬁ city obtained by the reader device with values 
obtained by the naked eye. We assessed the overall 
performance of the DPP T2 assay versus the RPR test by 
receiver-operating characteristic analyses. We estimated 
the empirical optimum cutoﬀ  value for the DPP T2 assay 
with the Liu method,21 which maximises the product of 
the sensitivity and speciﬁ city, and with the nearest to (0,1) 
method, which ﬁ nds the cutpoint on the receiver-
operating characteristic curve closest to (0,1). We used 
the optimum cutoﬀ  value to estimate sensitivity and 
speciﬁ city of the DPP T2 assay and compared values with 
those ascertained at a cutoﬀ  of greater than 35 or greater 
than 50, which were proposed by the manufacturer. 
To compare sensitivity and speciﬁ city at diﬀ erent cutoﬀ s, 
we used McNemar’s test.
We compared mean diﬀ erences in DPP optical density 
at several timepoints using the negative binomial 
generalised estimating equation (GEE) population-
averaged regression model. We did statistical analyses 
with Stata version 13.0. All tests were two-tailed, and 
we judged p less than 0·05 signiﬁ cant.
This study is registered with ClinicalTrials.gov, number 
NCT01841203.
Role of the funding source
Chembio Diagnostic Systems provided the DPP assay 
for use in the study, but otherwise, the funders of the 
study had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. 
The cor responding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
707 children were enrolled, of whom four withdrew 
from the study because of their unwillingness to 
undergo venepuncture. Of the 703 individuals tested, 
368 (52%) were boys and 335 (48%) were girls; the 
median age of participants was 11 years (IQR 7–14). 
504 participants were recruited from Lihir Island 
(group 1) and 199 were recruited from Karkar Island 
(group 2). 478 (68%) participants were suspected to 
have primary yaws and 225 (32%) had signs of 
secondary yaws. The recruitment and testing algorithm 
for participants is presented in ﬁ gure 1.
504 plasma samples (group 1) and 199 whole-blood 
specimens (group 2) were collected and used for 
504 tested by DPP 
  using plasma in 
  Lihir Laboratory
504 tested by RPR and 
  TPHA in Lihir 
  Laboratory
199 tested by DPP 
  using whole blood 
  in the field
199 tested by RPR and 
  TPHA in Lihir 
  Laboratory
707 eligible participants
3 withdrew
26 lost to 
 follow-up
1 withdrew
Group 1
507 enrolled in April, 2013, from  
  Lihir Island
Combined positive RPR/TPHA, 42·9%
504 clinically examined according to 
  WHO pictorial guide
Group 2
200 enrolled in October, 2013, from  
  Karkar Island
Combined positive RPR/TPHA, 35·7%
199 clinically examined according to 
  WHO pictorial guide
182 completed 
  follow-up
208 enrolled for 
  follow-up to 
  monitor DPP  
  optical density at  
  3 and 6 months
Figure 1: Recruitment and testing algorithm
DPP=Dual Path Platform assay. RPR=rapid plasma reagin test. TPHA=Treponema pallidum haemagglutination assay.
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assessment. Of 703 specimens tested, 287 (41%) had 
positive RPR and TPHA results, whereas 102 (15%) were 
reactive on TPHA alone, and 18 (3%) were positive for 
the RPR test alone. The remaining 296 (42%) specimens 
were non-reactive in both the treponemal and non-
treponemal reference tests. The 305 RPR-positive 
specimens were tested quantitatively (ﬁ gure 2); 
the DPP T2 (non-treponemal) assay was more often 
discordant at lower RPR titres (≤1:8). A signiﬁ cant 
increase was noted in optical density values of the 
DPP T2 assay, measured by the automated reader, with 
increasing RPR titre (p<0·0001; table 1).
Table 2 presents a comparison of both treponemal and 
non-treponemal DPP assays (T1 and T2) read by naked 
eye versus standard tests. The overall sensitivity of the 
DPP T1 assay was 88·4% and speciﬁ city was 95·2%, 
compared with TPHA. The DPP T2 assay showed a 
sensitivity of 87·9% and a speciﬁ city of 92·5% versus the 
RPR test. The ability of the DPP assay to detect both 
treponemal and non-treponemal (T1 and T2) antibodies, 
compared with the combination of positive TPHA and 
high-titre RPR test, showed an overall sensitivity of 93·9% 
(95% CI 89·5–96·8) and speciﬁ city of 83·6% (80·1–86·7). 
In prespeciﬁ ed subgroup analyses (table 2), the 
sensitivity of the DPP T2 assay for children with primary 
yaws was signiﬁ cantly higher than that for individuals 
with secondary yaws (diﬀ erence of proportions 12·6%, 
95% CI 4·0–22·8; p=0·005). The two types of specimen—
plasma and whole blood—had similar sensitivities 
and speciﬁ cities for detection of treponemal and 
non-treponemal antibodies.
Table 3 shows the sensitivity of the DPP assay to 
detect non-treponemal (T2) antibodies, according to 
RPR titre and by clinical stage and type of specimen. 
Among specimens with a high RPR titre (≥1:8), the 
overall sensitivity of the DPP T2 assay increased to 
94·1% and sensitivity was signiﬁ cantly higher in all 
subgroups, compared with specimens with lower RPR 
titres (≤1:4).
The area under the receiver-operating characteristic 
curve for the DPP T2 assay using automatic reading was 
0·947. The optimum cutoﬀ , identiﬁ ed by both the 
RPR titre Total 
(n=282)
p*
1:2 (n=45) 1:4 (n=41) 1:8 (n=31) 1:16 (n=28) 1:32 (n=38) 1:64 (n=55) 1:128 (n=30) 1:256 (n=12) 1:512 (n=2)
Optical density 
of DPP T2 assay
92·9 
(73·3)
184·0 
(135·8)
175·9 
(150·5)
267·2 
(187·8)
463·8 
(243·4)
457·5 
(232·0)
599·6 
(255·3)
547·2 
(252·7)
911·7 
(168·5)
276·9 
(252·4)
<0·0001
Data are geometric mean (SD). Data measured using an automated reader. DPP T2=Dual Path Platform (non-treponemal). RPR=rapid plasma reagin. *From log-normal 
regression model. 
Table 1: Optical density of DPP T2 assay, by RPR titre 
Sample 
size (n)
DPP T1 assay (naked eye) vs TPHA DPP T2 assay (naked eye) vs RPR test
Sensitivity (95% CI) p Speciﬁ city (95% CI) p Sensitivity (95% CI) p Speciﬁ city (95% CI) p
Total 703 88·4% (84·8–91·4) ·· 95·2% (92·2–97·3) .. 87·9% (83·7–91·3) ·· 92·5% (89·4–94·9) ··
Clinical stage
Primary 478 88·4% (84·0–91·9) >0·99* 96·0% (92·3–98·3) 0·412* 91·4% (86·8–94·7) 0·005* 91·5% (87·4–94·6) 0·427*
Secondary 225 88·5% (81·1–93·7) 93·8% (87·5–97·5) 78·8% (68·6–86·9) 94·3% (89·1–97·5)
Specimen
Plasma 504 87·5% (83·2–91·1) 0·455† 94·2% (90·1–97·0) 0·279† 88·0% (83·2–91·9) 0·838† 91·5% (87·5–94·5) 0·317†
Whole blood 199 91·3% (83·6–96·2) 97·2% (92·0–99·4) 87·3% (77·3–94·0) 94·5% (89·1–97·8)
In the study population, the frequency of positive TPHA was 55·3% and positive RPR test was 43·4%. DPP T1=Dual Path Platform (treponemal). DPP T2=Dual Path Platform 
(non-treponemal). RPR=rapid plasma reagin. TPHA=Treponema pallidum haemagglutination assay. *Comparison with secondary stage. †Comparison with whole blood.
Table 2: Sensitivity and speciﬁ city of DPP T1 and T2 assays
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512
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Figure 2: Seropositivity pattern of quantitative tests
DPP T2=Dual Path Platform T2 (non-treponemal) assay. RPR=rapid plasma reagin test.
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Liu method and the nearest to (0,1) method, was an 
optical density greater than 35, which gave a sensitivity 
of 89·8%, speciﬁ city of 90·5%, and correct classiﬁ cation 
of 90·0%. The sensitivity of T2 was increased slightly 
by use of automatic readers compared with the naked 
eye when the optical density cutoﬀ  was set at greater 
than 35, but it was lower when the cutoﬀ  was set at 
greater than 50 (table 4).
208 children in group 1 who had a positive DPP T1 
assay and a reaction on the DPP T2 assay at an optical 
density greater than 35 were selected for follow-up, to 
monitor changes in the DPP T2 assay over time. 
26 (13%) individuals could not be traced; the remaining 
182 were included in subsequent comparative analyses 
at 3 and 6 months after treatment. The intensity of 
the DPP T2 assay decreased signiﬁ cantly after treat-
ment (p<0·0001; ﬁ gure 3), with mean values at baseline 
of 390·4 (95% CI 344·1–436·7), at 3 months of 
101·5 (80·3–122·7), and at 6 months of 31·5 (21·6–41·5). 
Rates of seroreversion after treatment (ie, optical 
density becoming negative, cutoﬀ  ≤35) were 47·8% 
(95% CI 40·5–55·1) at 3 months and 78·6% (72·6–84·6) 
at 6 months. If a fourfold reduction in optical density by 
6 months were a second criterion for serological cure 
(after optical density ≤35), 173 (95%) of 182 participants 
would be judged cured at 6 months. Nine (5%) patients 
did not meet either criterion for serological cure: 
two (1%) had a sustained increase in optical density, 
suggesting treatment failure; and seven (4%) had an 
initial fourfold decline in optical density at 3 months 
followed by an increase in the titre, suggesting 
reinfection after cure.
38 samples were retested at the independent micro-
biology unit in Australia. Agreement was recorded for 
37 (97%) TPHA and 35 (92%) RPR tests. Two (5%) 
discrepant samples for RPR were read as negative in the 
Lihir Medical Centre laboratory and were weakly positive 
(ie, titre 1:2) in the reference laboratory.
Discussion
In the communities we studied, a rapid and simple 
point-of-care DPP assay detected T pallidum pertenue 
infection with high speciﬁ city and sensitivity. For all 
children included in our study, both the treponemal and 
non-treponemal DPP assays had high sensitivity and 
speciﬁ city, and these values were similar in subgroups 
deﬁ ned according to clinical characteristics and type of 
specimen tested (whole blood vs plasma).
The sensitivity of the DPP treponemal assay for yaws 
was slightly lower than expected (for syphilis it is more 
than 94–96%, vs 88% in our study), but the sensitivity of 
the non-treponemal assay was similar to that seen in 
syphilis (about 88%).15,16 When we excluded children 
with low-titre RPR tests (ie, ≤1:4) from our analysis 
(102 [33%] of 305 RPR-positive), the sensitivity of the 
DPP T2 assay rose to 94%. These same specimens with 
low-titre RPR tests typically had low-intensity values of 
treponemal antibody, resulting in reduced sensitivity of 
the DPP T1 assay, but sensitivity rose to 97·9% in 
patients with an RPR titre of 1:8 or higher, suggesting 
that these individuals might have had latent yaws 
(infected a long time ago), with skin lesions caused by 
other infectious agents.22
During a 6-month follow-up period, using an 
automated reader to measure the intensity of the 
non-treponemal rapid test line, we showed that DPP T2 
optical density progressively fell after yaws treatment. 
Either seroreversion or a fourfold reduction in optical 
density was attained in 95% of patients 6 months after 
treatment. The optical density values of the non-
treponemal assay have a similar response to the standard 
RPR titres that usually fall within 6–12 months.
Our study has several strengths. First, we assessed 
the DPP assays in two diﬀ erent well-characterised 
communities of Papua New Guinea with known high 
prevalence of yaws. Second, we implemented standard 
external quality-control procedures for RPR testing and 
TPHA at an independent reference laboratory, and 
reproducibility was good. Finally, in addition to visual 
reading of results, we used an automatic reader to 
measure the intensity of DPP test lines and provide an 
objective quantitative or qualitative result by setting a 
cutoﬀ  criterion. The automatic reader was helpful to 
conﬁ rm the reading obtained by the naked eye, and its use 
showed a small improvement in performance of the DPP 
assay. Measurement with the automatic reader has the 
RPR titre ≤1:4 RPR titre ≥1:8 p‡ 
Sample 
size (n)*
Sensitivity
(95% CI)
Sample 
size†
Sensitivity
(95% CI)
Total 500 75·5% (66·0–83·5) 601 94·1% (89·9–96·9) <0·0001
Clinical stage
Primary 324 84·8% (73·9–92·5) 412 94·2% (89·2–97·3) 0·035
Secondary 176 58·3% (40·8–74·5) 189 93·9% (83·1–98·7) 0·0001
Specimen
Plasma 362 77·2% (67·2–85·3) 412 95·1% (90·1–98·0) 0·0001
Whole blood 138 60·0% (26·2–87·8) 189 91·8% (81·9–97·3) 0·019
DPP T2=Dual Path Platform (non-treponemal). RPR=rapid plasma reagin. *Including specimens with an RPR titre of 
1:2 and 1:4, and those negative for the RPR test. †Including specimens with an RPR titre ≥1:8, and those negative for 
the RPR test. ‡Comparison between RPR test titre ≤1:4 and RPR test titre ≥1:8.
Table 3: Sensitivity of DPP T2 assay (read by naked eye) according to RPR titre
Sensitivity (95% CI) p* p† Speciﬁ city (95% CI) p* p†
Naked eye 87·9% (83·7–91·3) ·· ·· 92·5% (89·4–94·9) ·· ··
Automated reader
Cutoﬀ  >35 89·8% (85·9–93·0) 0·058 ·· 90·5% (87·1–93·2) 0·102 ··
Cutoﬀ  >50 84·9% (80·4–88·7) 0·029 0·0001 94·2% (91·5–96·3) 0·162 0·0001
DPP T2=Dual Path Platform (non-treponemal). RPR=rapid plasma reagin. *Comparison with results ascertained by 
naked eye. †Comparison between cutoﬀ s >35 and >50.
Table 4: Sensitivity and speciﬁ city of the DPP T2 assay, according to reading method
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potential to monitor changes in density of non-treponemal 
antibodies (corresponding to titre) and allow for 
quantitative serological follow-up. However, electricity 
requirements and costs could be a barrier to routine use of 
this automated reader in resource-limited settings in 
yaws-endemic countries.
The prevalence of active and latent yaws in this cohort 
and in other communities in the Paciﬁ c Islands is very 
high.19,23–25 About half the individuals screened at the 
community level who showed symptoms of yaws had 
dually positive TPHA and RPR serology. Moreover, 15% 
of people had ﬁ ndings consistent with past or treated 
infection—ie, they were positive by treponemal assay but 
negative with non-treponemal testing. The high 
proportion of individuals with a discordance in 
treponemal and non-treponemal results highlights the 
limitations of using a treponemal test alone for yaws 
surveillance. The value of the new DPP test lies in the non-
treponemal part, which can give immediate and accurate 
results for a diagnosis of active and untreated yaws 
infection rather than rely on a distant laboratory that is 
able to do RPR testing. Moreover, as reported in our 
study, sensitivity and speciﬁ city of the DPP assay did not 
diﬀ er between whole-blood samples and plasma 
specimens. The ability to use whole blood from a ﬁ nger 
stick provides a point-of-care solution for yaws 
eradication. This advance is important for a disease that 
is typically prevalent in poor, isolated, rural settings in 
tropical areas.
For countries aiming to eradicate yaws, programmes 
should account for the variability of performance of the 
DPP assay, which is associated with low-titre RPR 
positivity. Furthermore, they should build in initiatives 
such as detection of new infectious cases and post-zero 
case surveillance.
A dual point-of-care test could be used before rounds of 
mass treatment; at this stage, the DPP test could identify 
dually positive patients with skin ulcers who have 
latent yaws and a lesion caused by bacteria other than 
T pallidum pertenue. However, after mass treatment 
rounds, the number of asymptomatic seroreactors will 
fall sharply and reliability of the DPP test to help in the 
diagnosis of new infectious cases will rise inversely. 
Our follow-up results 6 months after treatment, with a 
high proportion of seroreversion, support use of the DPP 
assay for active detection of new yaws cases after mass 
treatment. During resurveys, all people with ulcers 
should be screened with the DPP test and, if dually 
positive, both the index case and all their contacts should 
receive treatment with azithromycin. Those with ulcers 
but who are not positive on the DPP assay could be given 
syndromic treatment and followed up further.
For post-zero case surveillance, when the prevalence of 
yaws falls to very low levels, the positive predictive value of 
the non-treponemal line will decrease and, with a 
speciﬁ city of 92%, a moderate proportion of positive 
results will be false positives. A more speciﬁ c test might be 
needed to ensure that transmission has been interrupted.
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Figure 3: Optical density of DPP assay during the study
Optical density was measured by an automated reader. Red dots indicate mean 
values and error bars represent 95% CIs. (Upper panel) DPP T1 (treponemal) 
assay. (Lower panel) DPP T2 (non-treponemal) assay. DPP=Dual Path Platform.
Panel: Research in context
Systematic review
We searched PubMed up to April 1, 2013, with the terms: 
“yaws”, “syphilis”, “point-of-care”, “non-treponemal”, and 
“rapid plasma reagin”. We restricted our search to publications 
in English. We selected studies that assessed the accuracy of 
point-of-care tests in identifying the presence of 
non-treponemal antibodies in people with yaws. We found 
three studies15–17 that showed accuracy of a new, dual, 
point-of-care immunoassay detecting non-treponemal and 
treponemal antibodies in syphilis. However, we did not 
identify any study that explored yaws diagnosis with a 
non-treponemal point-of-care assay.
Interpretation
Our results provide substantial evidence that the new, 
point-of-care, Dual Path Platform (DPP) Syphilis Screen and 
Conﬁ rm assay can identify treponemal and non-treponemal 
antibodies in people with suspected clinical yaws. This 
ﬁ nding represents a potentially useful advance in yaws 
diagnosis and control.
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If our ﬁ ndings are conﬁ rmed in subsequent studies, and 
the DPP assay were to become widely available at an 
aﬀ ordable price, it could help programmes to target yaws 
cases and contacts reliably and to identify new cases after 
mass treatment. Overall, the rate of overtreatment would 
be diminished considerably with use of the DPP 
non-treponemal and treponemal point-of-care assay, 
compared with the number of aﬀ ected individuals who 
would be detected if only a treponemal point-of-care test 
were used. WHO should advocate for making this test 
available in yaws-endemic countries as part of the renewed 
eradication eﬀ orts.
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